Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 17, Number 9—September 2011
Research

Seroepidemiologic Study of Pandemic (H1N1) 2009 during Outbreak in Boarding School, England

Sandra Johnson, Chikwe IhekweazuComments to Author , Pia Hardelid, Nika Raphaely, Katja Hoschler, Alison Bermingham, Muhammad Abid, Richard G. Pebody, Graham Bickler, John T. Watson, and Éamonn O’Moore
Author affiliations: Author affiliations: Health Protection Agency, London, UK (S. Johnson, C. Ihekweazu, P. Hardelid, K. Hoschler, A. Bermingham, R. Pebody, G. Bickler, J. Watson); Health Protection Agency, Oxfordshire, UK (N. Raphaely, M. Abid, É. O’Moore)

Main Article

Table 2

Association of demographic characteristics and interventions with study participants’ reports of ARI during outbreak of pandemic (H1N1) 2009 at a boarding school, England*

Variable
No. participants
No. (%) with ARI
Odds ratio (95% CI)
Total 695 237 (34.1)
Demographics
Category
Students 469 187 (39.9) 2.53 (1.75–3.65)
Staff 226 50 (22.1) 1
Age group, y
13–15 219 75 (34.2) 1
16–18 250 112 (44.8) 1.55 (1.06–2.28)
20–49 111 32 (28.8) 0.70 (0.42–1.15)
>50 87 18 (20.7) 0.48 (0.26–0.86)
Sex, staff only†
F 109 24 (22.0) 1
M 117 26 (22.2) 0.98 (0.52–1.83)
Role, staff only
Nonteaching 135 26 (19.3) 1
Teaching
85
23 (27.1)
1.48 (0.78–2.82)
Interventions
Took antiviral drugs
No 198 81 (40.9) 1
Yes 393 110 (28.0) 0.55 (0.38–0.79)
Use of antiviral drugs: PEP vs. treatment dose
No antiviral drugs 198 81 (40.9) 1
Yes, PEP 352 78 (22.2) 0.40 (0.27–0.59)
Yes, treatment dose 41 32 (78.1) 4.87 (2.20–10.77)
Completion of PEP course of antiviral drugs†
No antiviral drugs 198 81 (40.9) 1
Not completed 51 14 (27.5) 0.44 (0.17–1.15)
Completed 294 62 (21.1) 0.38 (0.22–0.65)
Seasonal Influenza vaccine
No 216 66 (30.6) 1
Yes 425 161 (37.9) 1.35 (0.95–1.92)

*Categories in which the response was missing or unknown are shown in the Table A1. ARI, acute respiratory infection; CI, confidence interval; PEP, postexposure prophylaxis.
†Excluding those who reported taking the treatment dose of antiviral drugs.

Main Article

Page created: September 06, 2011
Page updated: September 06, 2011
Page reviewed: September 06, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external